Get the Stockscreener App
23.86
1.28%
-0.31
After Hours:
23.90
0.04
+0.17%
Alumis Inc stock is traded at $23.86, with a volume of 1.58M.
It is down -1.28% in the last 24 hours and up +109.30% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$24.17
Open:
$23.9
24h Volume:
1.58M
Relative Volume:
0.63
Market Cap:
$2.98B
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.89
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+21.98%
1M Performance:
+109.30%
6M Performance:
+593.60%
1Y Performance:
+206.29%
1-Day Range:
$23.36
$24.54
1-Week Range:
$19.55
$25.19
52-Week Range:
$2.7601
$25.19
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
23.86 | 3.01B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating - Insider Monkey
Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed? - simplywall.st
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis (ALMS) stock jumps as insider filings show $17 buys — what investors are watching next - TechStock²
Why Alumis Inc. Stock Is Surging Right Now - TipRanks
Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity - MarketBeat
Alumis' Meteoric Rise To $20 From $5 In Just 60 Days On Plaque Psoriasis Trial Results - Nasdaq
Alumis (ALMS) Price Target Increased by 79.14% to 36.28 - Nasdaq
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Follow On Equity Offering - simplywall.st
Insider Makes Bold Multimillion-Dollar Bet on Alumis Inc. - TipRanks
Insider Buying: Alumis (NASDAQ:ALMS) Director Purchases 588,235 Shares of Stock - MarketBeat
Aug Sectors: Will Alumis Inc stock benefit from automation2025 Performance Recap & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Akkaraju of Alumis buys shares worth $9.9 million By Investing.com - Investing.com Nigeria
Akkaraju of Alumis buys shares worth $9.9 million - Investing.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Hedge Fund and Insider Trading News: Bill Ackman, Ray Dalio, Warren Buffett, Balyasny Asset Management, Schonfeld Strategic Advisors, Renaissance Technologies, Anson Investments, Limoneira Co (LMNR), Alumis Inc (ALMS), and More - Insider Monkey
Alumis (NASDAQ:ALMS) Reaches New 1-Year High on Insider Buying Activity - MarketBeat
Alumis Inc stock hits all-time high at 22.33 USD - Investing.com India
Why Alumis Inc. Stock Is Quietly Surging Higher - TipRanks
Support Test: Is Alumis Inc stock a buy on dipsMarket Activity Summary & Weekly Top Gainers Alerts - Bộ Nội Vụ
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
Latham & Watkins Advises on Alumis’ Upsized US$345 Million Public Offering of Common Stock - Legal Desire Media and Insights
Insider Buying: Alumis (NASDAQ:ALMS) Major Shareholder Buys 411,764 Shares of Stock - MarketBeat
Alumis Insider Bought Shares Worth $6,999,988, According to a Recent SEC Filing - marketscreener.com
Alumis (NASDAQ:ALMS) Major Shareholder Buys $6,999,988.00 in Stock - MarketBeat
Foresite Labs buys Alumis (ALMS) shares worth $7 million - Investing.com
Foresite Labs buys Alumis (ALMS) shares worth $7 million By Investing.com - Investing.com Canada
Alumis (ALMS) director Tananbaum buys shares worth $6.99m By Investing.com - Investing.com South Africa
Foresite Capital buys Alumis (ALMS) shares worth $7m By Investing.com - Investing.com South Africa
Foresite Capital buys Alumis (ALMS) shares worth $7m - Investing.com
Aug Decliners: Is Alumis Inc gaining market share2025 Price Momentum & Low Drawdown Trading Strategies - baoquankhu1.vn
Investment Review: Is Alumis Inc gaining market shareShort Setup & Verified Momentum Stock Watchlist - baoquankhu1.vn
Alumis Stock Skyrockets Amid Significant Drug Trial Success - StocksToTrade
Alumis Stock Soars After Phase 3 Trial Success - timothysykes.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Alumis announces phase 3 trial of envudeucitinib met all primary endpoints - MSN
Alumis raises $345.1 million in upsized public offering By Investing.com - Investing.com India
Alumis raises $345.1 million in upsized public offering - Investing.com
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Alumis Inc. Announces Closing of $345.1 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Can Alumis Inc. stock hit record highs againPerformance Line Overview & updated model highlights and notes - ulpravda.ru
Alumis launches sizable common stock public offering - TipRanks
Alumis prices upsized public offering of common stock at $17 per share - Investing.com Nigeria
Can Alumis Inc. stock maintain growth trajectoryJuly 2025 Movers & Verified Momentum Stock Watchlist - ulpravda.ru
What's Going On With Alumis Stock Thursday? - Sahm
Alumis (ALMS) Is Up 83.6% After Phase 3 Psoriasis Win And NDA PlanHas The Bull Case Changed? - Sahm
Why Alumis Inc. stock is favored by top institutionsEarnings Risk Summary & Capital Efficient Trade Techniques - ulpravda.ru
Will Alumis Inc. stock beat EPS estimatesMarket Rally & Long-Term Growth Plans - ulpravda.ru
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Why Alumis Inc. stock could outperform in 20252025 Volatility Report & High Accuracy Swing Trade Signals - ulpravda.ru
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):